| 000 | 02655 a2200757 4500 | ||
|---|---|---|---|
| 005 | 20250514234515.0 | ||
| 264 | 0 | _c20051031 | |
| 008 | 200510s 0 0 eng d | ||
| 022 | _a0364-5134 | ||
| 024 | 7 |
_a10.1002/ana.20553 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aAsimiadou, Stiliani | |
| 245 | 0 | 0 |
_aProtection with estradiol in developmental models of apoptotic neurodegeneration. _h[electronic resource] |
| 260 |
_bAnnals of neurology _cAug 2005 |
||
| 300 |
_a266-76 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 | _aAnimals, Newborn |
| 650 | 0 | 4 |
_aApoptosis _xdrug effects |
| 650 | 0 | 4 |
_aBicuculline _xpharmacology |
| 650 | 0 | 4 |
_aBlotting, Western _xmethods |
| 650 | 0 | 4 |
_aBrain _xdrug effects |
| 650 | 0 | 4 |
_aCaenorhabditis elegans Proteins _xpharmacology |
| 650 | 0 | 4 |
_aCell Count _xmethods |
| 650 | 0 | 4 | _aCells, Cultured |
| 650 | 0 | 4 |
_aCerebral Cortex _xcytology |
| 650 | 0 | 4 | _aDisease Models, Animal |
| 650 | 0 | 4 | _aDizocilpine Maleate |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aDrug Interactions |
| 650 | 0 | 4 |
_aEstradiol _xtherapeutic use |
| 650 | 0 | 4 |
_aEstrogen Antagonists _xpharmacology |
| 650 | 0 | 4 |
_aExtracellular Signal-Regulated MAP Kinases _xmetabolism |
| 650 | 0 | 4 |
_aGABA Antagonists _xpharmacology |
| 650 | 0 | 4 |
_aHypoxia _xcomplications |
| 650 | 0 | 4 |
_aImmunohistochemistry _xmethods |
| 650 | 0 | 4 |
_aIn Situ Nick-End Labeling _xmethods |
| 650 | 0 | 4 |
_aMembrane Potentials _xdrug effects |
| 650 | 0 | 4 |
_aNeurodegenerative Diseases _xetiology |
| 650 | 0 | 4 |
_aNeurons _xdrug effects |
| 650 | 0 | 4 |
_aNeuroprotective Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aPatch-Clamp Techniques _xmethods |
| 650 | 0 | 4 | _aPhenobarbital |
| 650 | 0 | 4 | _aPhenytoin |
| 650 | 0 | 4 |
_aProtein Serine-Threonine Kinases _xmetabolism |
| 650 | 0 | 4 |
_aProto-Oncogene Proteins _xmetabolism |
| 650 | 0 | 4 | _aProto-Oncogene Proteins c-akt |
| 650 | 0 | 4 | _aRats |
| 650 | 0 | 4 | _aRats, Wistar |
| 650 | 0 | 4 | _aReceptors, GABA-A |
| 650 | 0 | 4 |
_aSilver Staining _xmethods |
| 650 | 0 | 4 |
_aTamoxifen _xpharmacology |
| 700 | 1 | _aBittigau, Petra | |
| 700 | 1 | _aFelderhoff-Mueser, Ursula | |
| 700 | 1 | _aManthey, Daniela | |
| 700 | 1 | _aSifringer, Marco | |
| 700 | 1 | _aPesditschek, Stefanie | |
| 700 | 1 | _aDzietko, Mark | |
| 700 | 1 | _aKaindl, Angela M | |
| 700 | 1 | _aPytel, Maria | |
| 700 | 1 | _aStudniarczyk, Dorota | |
| 700 | 1 | _aMozrzymas, Jerzy W | |
| 700 | 1 | _aIkonomidou, Chrysanthy | |
| 773 | 0 |
_tAnnals of neurology _gvol. 58 _gno. 2 _gp. 266-76 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/ana.20553 _zAvailable from publisher's website |
| 999 |
_c15703364 _d15703364 |
||